Consulting Report

Henderson, N., Firth, I., Errea, M., Skedgel, C. and Jofre-Bonet, M.

Consulting Report
September 2021

Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the National Institute of Health and Care Excellence (NICE) by providing an auxiliary appraisal route for highly specialized technologies. However, concerns have been raised regarding the appraisals of medicines that don’t meet the strict criteria and are, therefore, evaluated via the standard appraisal route (STA).

Hitch, J., Firth, I., Hampson, G., Jofre-Bonet, M., Garau, M., Garrison, L. and Cookson, G.

 

Consulting Report
September 2021

The US spends more on healthcare than any other country in the world. H.R. 3 is a recent policy proposal aimed at reducing national spending on prescription drugs, one component of overall healthcare spending. Drug manufacturers would be required to negotiate prices with the US government, and prices would be capped at a level based on the prices of the drug in a set of foreign countries. Evaluation of a policy with such large potential impact on pharmaceutical revenues must consider potential negative effects on incentives to innovate.

Rodes Sanchez, M., Rachev, B., Spencer, J., Sharma, I., Tantri, A., Towse, A., Mitrovich, R. and Steuten, L.

Consulting Report
September 2021

By placing a strain on health care systems and the global economy, the COVID-19 pandemic clearly shows the need to more comprehensively understand both supply- and demand-side aspects of a “healthy” vaccines market that can meet public health demand over time and across dynamic events. The goal of a healthy vaccines market, as defined for this study, is to support sustainable innovation and equitable access to address public health needs.

Firth, I., Schirrmacher, H., Hampson, G. and Towse, A.

Consulting Report
June 2021

Early access schemes (EASs) can enable access to medicines prior to completion of the regulatory process. EASs allow national regulators to issue an initial positive assessment of the balance between benefits and risks for groups of patients on the basis of early clinical trial data. The main aim is to meet the needs of patients facing exceptional challenges i.e., those with seriously debilitating or life-threatening diseases and no satisfactory treatment alternative.

Firth, I., Schirrmacher, H., Zhang, K., Towse, A. and Hampson, G.

Consulting Report
May 2021

Gene therapies represent a paradigm shift in medicine, with the potential to address the root causes of chronic diseases. They offer one-time treatment regimens and, in some cases, potentially a cure. As a result, they offer transformative value for patients, physicians, health systems and society. However, with the prospect of more gene therapy approvals there is concern in Europe that these technologies could threaten the financial sustainability of health systems.

Berdud, M., Jofre-Bonet, M., Rodes-Sanchez, M., Towse, A. 

Consulting Report
May 2021

After the shock caused by the first wave of COVID-19, discovering vaccines against the virus and administering them quickly to the population became the utmost priority worldwide, especially once subsequent waves of COVID-19 were inevitable. Not only incentivising the research on vaccines and authorising them quickly, but managing optimally the portfolio of vaccine candidates and establishing an efficient distribution plan became paramount to the success of this instrument.

Consulting Report
April 2021

We have now published an interactive report on our recent debate, The Promise of Gene Therapy: Are we Ready?

In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In the interactive report we highlight our 5 key takeaways from the debate with clips, quotes and highlights.

Brassel, S., Neri, M. and Steuten, L. 

Consulting Report
February 2021

The COVID-19 pandemic has revealed the broad and devastating health, economic and societal impact of a highly infectious and deadly disease. In addition to the human suffering of COVID-19 patients, the pandemic is taking a heavy toll patients’ families, friends, colleagues, and other social networks. On healthcare staff working around the clock, wave after wave. And on the capacity of the NHS, buckling under the pandemic pressures with consequences that will last for years. Then, there’s the disastrous economic impact, crippling economies in the UK and worldwide.

Towse, A., Lothgren, M., Steuten, L. and Bruce, A. 

Consulting Report
February 2021

Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the expected additional benefits from adding a new medicine to a currently reimbursed medicine represents value for money to the health system. In markets that utilise cost-per-QALY approaches for assessing value, a clinically effective medicine might even be found to be “not cost-effective at zero price” when used as part of a regimen that increases treatment duration.

Rodes Sanchez, M., Henderson, N. and Steuten, L. 

Consulting Report
August 2020

Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and policy hurdles related to evidence development and acceptance, value assessment and reimbursement pathways, and diagnostic infrastructure availability.

Pages

Subscribe to RSS - Consulting Report